NCT07020780View on ClinicalTrials.gov

5 fr Ultrahypofractionated WBI and SIB for Breast Cancer With Unfavorable Characteristics

NARecruitingINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2035

Conditions
Breast Cancer
Interventions
RADIATION

Adjuvant 5 fractions whole breast irradiation with simultaneous integrated boost to the tumor bed

Experimental arm (arm 1-five fractions WBI) patients will be treated to a total dose (TD) of 26 Gy in 5 fractions to whole breast, and a simultaneous integrated boost (SIB) to a TD of 30 Gy to the tumor bed, while arm 2-fifteen-fractions WBI patients with 40 Gy/15 fractions to PTV, and 48 Gy SIB to the tumor bed.

Trial Locations (1)

20132

RECRUITING

IRCCS San Raffaele Scientific Institute, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT07020780 - 5 fr Ultrahypofractionated WBI and SIB for Breast Cancer With Unfavorable Characteristics | Biotech Hunter | Biotech Hunter